MOTIVATION LETTER Addiction destroys more lives globally than cancer and heart disease combined, yet the pharmaceutical industry has not approved a single mechanistically novel anti-addiction drug in over two decades. The Conjunctive Consolidation Threshold model, or CCT, is a tripartite pharmacological framework that prevents reward-memory encoding before it stabilizes in the brain. My computational validation shows an 85.8 percent reduction in encoding probability, from 0.855 to 0.122, with a super-additivity effect of 12.8 percentage points beyond the sum of individual drug actions. All five pre-registered hypotheses, H1 through H5, were confirmed using ODE/RK45 numerical integration and Bayesian MCMC population dynamics. A provisional patent on the core architecture is filed for Q3 2026. IndieBio funds early-stage biotech ventures that can reach a clear inflection point within three to four months. My venture is a validated computational platform with three operational tools: IMPRINT for addiction-liability screening, TOPOLOGIX for topological data analysis of drug-protein interactions using persistent homology and bipartite simplicial complexes, and GATE for BCI neural-stimulation safety evaluation. The hERG cardiotoxicity MVP in TOPOLOGIX already demonstrates the platform's ability to flag off-target risks before wet-lab investment. The CCT model itself is documented in three sole-authored preprints on OSF and Zenodo, with a review article currently under peer review at Neuroscience and Biobehavioral Reviews. Endorsements from Kent Berridge at Michigan, Samuel Gershman at Harvard, Nathaniel Daw at Princeton, and Marcelo Mattar at NYU confirm the scientific credibility of the framework. IndieBio's emphasis on founder-market fit and commercial scalability aligns with my background. I hold a B.Pharm from the University of Ibadan with a German-equivalent grade of 1.9, am a PCN-licensed pharmacist, and currently serve as National Product Manager at Synthcare in Lagos. I built the entire CCT pipeline independently using Python, PyMC, scipy, and RDKit, and deployed the platforms on Supabase and Node.js. The addiction therapeutics market is valued at over 10 billion dollars annually, with no adequate computational screening tools for pre-clinical liability assessment. IMPRINT alone can serve as a de-risking service for every major pharmaceutical company developing CNS drugs. The programme asks for a clear path to milestones within the accelerator timeline. In the first month, I will finalize the GATE platform's integration with the CCT model for closed-loop safety predictions. In month two, I will onboard two beta-testing partners from the Nigerian neuroscience research network and begin data collection for a validation study comparing IMPRINT predictions against published clinical trial outcomes. By month three, I will have a commercial licensing term sheet for IMPRINT with at least one pharmaceutical partner and a Series A fundraising deck based on the validation data. Relocation to the United States is feasible for the duration of the programme, and remote participation is also possible given my existing infrastructure on AWS and HPC clusters. The CCT model was developed in Lagos, Nigeria, where the burden of substance use disorders is rising sharply and computational pharmacology resources are scarce. IndieBio's support would enable me to scale this framework from an independent research project into a commercial entity that addresses a global health disparity while generating revenue from the first year. SHORT ESSAY: PROBLEM AND SOLUTION The problem is that addiction treatment has not advanced mechanistically since the 1990s. Current pharmacotherapies, such as naltrexone and buprenorphine, target receptor systems after addiction is established. They do not prevent the initial encoding of reward-memory associations that drive compulsive drug-seeking behavior. The result is a 40 to 60 percent relapse rate within one year across all substance use disorders, costing the United States alone over 740 billion dollars annually in healthcare, criminal justice, and lost productivity. The CCT model solves this by intervening at the moment of memory consolidation. The framework identifies a conjunctive threshold where three pharmacological mechanisms, dopamine D1 receptor antagonism, NMDA receptor partial agonism, and calcium/calmodulin-dependent protein kinase II inhibition, act synergistically to prevent the stabilization of reward-context associations. The mathematical specification, published on OSF, defines the threshold as a function of drug concentration, receptor occupancy, and temporal overlap of administration. The Bayesian population dynamics model, published on Zenodo, predicts that a single combined dose administered within 30 minutes of a drug-taking event reduces encoding probability by 85.8 percent. The differentiation from existing approaches is clear. No current therapy targets the consolidation window. No existing computational model predicts the super-additive effect of a three-drug combination at sub-therapeutic doses. The CCT framework is platform-agnostic and can be adapted to any addictive substance, from opioids to alcohol to stimulants. The provisional patent protects the core architecture, and the endorsements from leading computational and affective neuroscientists provide external validation that this is a mathematically grounded, testable intervention. SHORT ESSAY: COMMERCIAL VIABILITY The commercial model has three revenue streams. First, IMPRINT as a software-as-a-service platform for pharmaceutical companies conducting preclinical addiction-liability screening. The current standard is behavioral assays in rodents costing 50,000 to 100,000 dollars per compound. IMPRINT provides a computational prediction in under 24 hours at a fraction of the cost. The target price is 5,000 dollars per compound per screen, with a projected addressable market of 500 compounds per year across the top 20 pharmaceutical companies. Second, TOPOLOGIX as a drug-protein interaction analysis tool for off-target toxicity prediction, with the hERG cardiotoxicity module as the initial product. Third, a licensing agreement for the CCT combination therapy itself once clinical trials confirm the computational predictions. The total addressable market for addiction therapeutics is 10.5 billion dollars globally, growing at 6.2 percent compound annual growth rate. The screening and de-risking market for CNS drugs is an additional 2.8 billion dollars. The venture requires 250,000 dollars from IndieBio to complete the validation study, hire one additional computational biologist, and file the provisional patent in full. The projected break-even point is month 18, with a revenue target of 500,000 dollars by the end of year two. CHECKLIST - [ ] Complete IndieBio online application form at the provided URL - [ ] Upload motivation letter as PDF - [ ] Upload short essay on problem and solution as PDF - [ ] Upload short essay on commercial viability as PDF - [ ] Attach CV or resume with full publication list and ORCID - [ ] Attach links to three preprints on OSF and Zenodo - [ ] Attach provisional patent filing receipt or confirmation - [ ] Provide two letters of reference from named endorsers (Berridge, Gershman, Daw, or Mattar) - [ ] Prepare three-minute video pitch describing the venture and the ask - [ ] Confirm eligibility for US-based accelerator participation or remote option EDITOR NOTES - Eligibility risk: IndieBio is a US-based accelerator and typically requires founder incorporation in the United States or a clear path to incorporation. Eniola is a Nigerian citizen currently in Lagos. Confirm whether IndieBio accepts international founders and whether visa support is provided. If not, the remote participation option must be explicitly negotiated before submission. - Fact verification needed: The 10.5 billion dollar figure for the addiction therapeutics market should be sourced from a specific market research report, such as Grand View Research or GlobalData. The 500 compounds per year estimate for the addressable market should be verified against industry data on CNS drug development pipelines. - Gap: The profile does not specify whether Eniola has any prior entrepreneurial experience, such as founding a company, raising angel investment, or participating in a previous accelerator. If none exists, the application should acknowledge this and frame the independent research output as equivalent proof of execution ability. - Gap: The profile mentions a co-authored paper in Alcohol under review but does not specify the topic or Eniola's contribution. Clarify this before submission to avoid questions during due diligence. - Gap: The provisional patent is listed as Q3 2026, which is the current quarter. Confirm that the filing has been submitted or is in final preparation. IndieBio will likely request the patent number or filing receipt.